



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

904.OUTCOMES RESEARCH-NON-MALIGNANT CONDITIONS

Health Related Quality of Life in Patients with Primary ITP Compared with Population Norms: A Multicenter Retrospective Analysis of Data from Norwegian ITP Registry

Riccardo Tomasello, MD^{1,2}, Lamy Garabet^{3,4,5}, Heidi Pettersen⁶, Hoa Tran, MD PhD⁷, Mazdac Tavoly, MD PhD⁶, Galina Tsykunova, MD⁸, Eirik Tjønnfjord, MD⁹, Mariasanta Napolitano, MDPhD^{10,11}, Waleed Ghanima, MDPhD^{12,13,14}

¹ University of Palermo, Palermo, Italy

² Departments of Research and Haemato-oncology, Østfold Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

³ Department of research, Østfold Hospital, Fredrikstad, Norway

⁴ Department of Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital, Lørenskog, Norway

⁵ Center of Laboratory Medicine, Østfold Hospital, Grålum, Norway

⁶ Department of Research, Østfold Hospital, Grålum, Norway, Grålum, Norway

⁷ Akershus University Hospital, Lørenskog, NOR

⁸ Baerum Hospital, Baerum, Norway

⁹ Department of Internal Medicine, clinic for thrombosis, Kalnes Hospital Trust, Grålum, Norway

¹⁰ Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo, ITA

¹¹ University of Palermo, Palermo, ITA

¹² Weill Cornell Medical College, New York, NY

¹³ Østfold Hospital, Grålum, Norway

¹⁴ Østfold Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Introduction: Immune thrombocytopenia (ITP) is characterized by thrombocytopenia and varying grades of bleeding manifestations. Many patients develop a fear of bleeding, which can impact their health-related quality of life (HRQoL). In addition, often necessary lifestyle adjustments as well as treatment-related side effects may further reduce HRQoL.

Aims: to estimate HRQoL in adult patients diagnosed with ITP and to compare their HRQoL to that of the general population using the EuroQol-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire.

Methods: Data from the Norwegian ITP (NOR-ITP) Registry was used. Adult ITP patients registered in NOR-ITP from Dec 2016 to May 2023 were included in this study. Patients included in NOR-ITP complete the EQ-5D-3L questionnaire, when included in the registry and then annually as part of their scheduled follow-up. In patients who had completed several EQ-5D-3L questionnaires, the most recent one was used. The age-adjusted Norwegian EQ-5D-3L populations norms were used as reference values for Index and VAS scores. Missing data were replaced using multiple imputation.

Results: Median (IQR) age of 247 patients was 57 years (34); M:F ratio = 1:1.5. ITP was newly diagnosed in 18 (7%), persistent in 14 (6%), and chronic in 215 (87%) patients. Platelet count was $>50 \times 10^9/L$ in 166 (67%) patients, between 31 and $50 \times 10^9/L$ in 15 (6%), and $< 30 \times 10^9/L$ in 18 (7%), unknown for 19% (48). Thirty-nine (16%) patients were never treated for ITP, 80 (32%) patients had remission induced by glucocorticoids +/- IVIGs, and 128 (52%) were treated with second-line agents. Ongoing treatment was an immunosuppressive agent (i.e. glucocorticoids +/- IVIGs, rituximab (received during the last 3 months), azathioprine, cyclosporine-A, mycophenolate mofetil) in 43 (17%) patients, a thrombopoietin receptor agonist in 42 (17%) patients, while 162 (66%) were off-treatment. Median time from diagnosis of ITP to most recent EQ-5D questionnaire was 4 (10) years. Figure 1a displays the frequency of reported problems (levels 2 and 3) in ITP patients compared to the population norms. ITP patients reported significantly more problems in 4 out of 5 domains. EQ-5D index score was significantly lower in ITP patients compared to the general population [Mean (SD) = 0.790 (0.23) vs 0.830 ([0.041]; p-value 0.007]. Likewise, we found VAS to be significantly lower in ITP patients compared to the general population [Mean (SD) = 70.82 (21.09) vs 77.32 (5.554); p-value 0.0001]. Within the ITP cohort, we found significantly lower VAS scores in ITP patients receiving ongoing treatment compared to those off treatment (p-value 0.01), as shown in figure 1b. However, no significant difference was found concerning

Index scores when comparing patients with ongoing to off-treatment. Comparing index scores and VAS according to platelet count category (<30 ; $31-50$; $>50 \times 10^9/L$) and the phase of ITP did not reveal any significant differences.

Conclusion: This study is the first to evaluate HR-QoL using EQ-5D in a well-characterized cohort of patients with ITP. In line with existing evidence, using other HRQoL instruments, we found significantly reduced HRQoL in ITP patients compared to the general population. ITP patients receiving ongoing treatment had worse HRQoL compared to those off-treatment. Limitations of this study are the long time period between diagnosis and completing the questionnaire, the observational and retrospective study design, and the lack of predictors for HRQoL.

Disclosures Garabet: Grifols: Honoraria. **Pettersen:** Sanofi: Honoraria. **Tran:** GRIFOLS: Honoraria; Sobi: Honoraria; Novartis: Honoraria. **Tsykunova:** GRIFOLS: Honoraria; Sobi: Honoraria. **Tjønnfjord:** GRIFOLS: Honoraria; Sobi: Honoraria; Novartis: Honoraria. **Ghanima:** cellphire: Consultancy, Honoraria; Sobi, Pfizer: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Kedrion: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Grifols: Consultancy, Honoraria; UCB: Consultancy, Honoraria; Argenx: Consultancy, Honoraria; BMS: Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; hibio: Consultancy, Honoraria; alpine: Consultancy, Honoraria.




Figure 1

<https://doi.org/10.1182/blood-2023-188445>